What is early lung cancer?

Pasic, Arifa; Postmus, Pieter E.; Sutedja, Tom G.

doi:10.1016/j.lungcan.2004.01.024

Cited by 28 publications

(3 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sub-centimeter lung cancer mainly appears at the early stage and is commonly determined to be no later than pT1aN0M0. Nevertheless, there are still limited data in surgical and pathological reports regarding early pulmonary lesions classified as pT1N0M0, especially those ≤1 cm in size, which are defined as sub-centimeter lung cancer with no sign of nodal involvement and metastasis ( 39 ). There is emerging evidence revealing that sub-centimeter lung cancer exhibits distinctive characteristics.…”

Section: Sub-centimeter Lung Cancermentioning

confidence: 99%

Advancements in the diagnosis and treatment of sub‑centimeter lung cancer in the era of precision medicine (Review)

Wang,

Shi,

Liu

2024

Mol Clin Oncol

View full text Add to dashboard Cite

Lung cancer is the malignancy with the highest global mortality rate and imposes a substantial burden on society. The increasing popularity of lung cancer screening has led to increasing number of patients being diagnosed with pulmonary nodules due to their potential for malignancy, causing considerable distress in the affected population. However, the diagnosis and treatment of sub-centimeter grade pulmonary nodules remain controversial. The evolution of genetic detection technology and the development of targeted drugs have positioned the diagnosis and treatment of lung cancer in the precision medicine era, leading to a marked improvement in the survival rate of patients with lung cancer. It has been established that lung cancer driver genes serve a key role in the development and progression of sub-centimeter lung cancer. The present review aimed to consolidate the findings on genes associated with sub-centimeter lung cancer, with the intent of serving as a reference for future studies and the personalized management of sub-centimeter lung cancer through genetic testing.

show abstract

Section: Sub-centimeter Lung Cancermentioning

confidence: 99%

Advancements in the diagnosis and treatment of sub‑centimeter lung cancer in the era of precision medicine (Review)

Wang,

Shi,

Liu

2024

Mol Clin Oncol

View full text Add to dashboard Cite

show abstract

“…Lung cancer is the main cancer in the world today with highest number of deaths (1.4 million) . Currently, auto‐fluorescence bronchoscopy (AFB) in conjunction with white light bronchoscopy (WLB) plays a definite clinical role in localizing preinvasive lung lesions inside the main airways . However, AFB for the detection of carcinoma in situ (CIS) and high grade dysplastic lesions showed a low specificity with a high false positive rate .…”

Section: Clinical Applications In Cancer Diagnosismentioning

confidence: 99%

Real‐time in vivo cancer diagnosis using raman spectroscopy

Wang

Zhao

Short

et al. 2014

Journal of Biophotonics

120

View full text Add to dashboard Cite

Raman spectroscopy has becoming a practical tool for rapid in vivo tissue diagnosis. This paper provides an overview on the latest development of real-time in vivo Raman systems for cancer detection. Instrumentation, data handling, as well as oncology applications of Raman techniques were covered. Optic fiber probes designs for Raman spectroscopy were discussed. Spectral data pre-processing, feature extraction, and classification between normal/benign and malignant tissues were surveyed. Applications of Raman techniques for clinical diagnosis for different types of cancers, including skin cancer, lung cancer, stomach cancer, oesophageal cancer, colorectal cancer, cervical cancer, and breast cancer, were summarized. Schematic of a real-time Raman spectrometer for skin cancer detection. Without correction, the image captured on CCD camera for a straight entrance slit has a curvature. By arranging the optic fiber array in reverse orientation, the curvature could be effectively corrected.

show abstract

“…Lung cancer is one of the most common cancers worldwide, 80 to 85% of cases are non-small cell lung cancer (NSCLC). 1 , 2 Epidermal growth factor receptor (EGFR) alterations are one of the most common driver mutations, found in 10–15% of Western patients and 40–50% of Asian patients with lung adenocarcinoma. 3–8 The most common EGFR mutations, also known as classic EGFR mutations, are EGFR exon 19 deletions and EGFR L858R point mutations on exon 21.…”

Section: Introductionmentioning

confidence: 99%

MARIPOSA: Can Amivantamab and Lazertinib Replace Osimertinib in the Front-Line Setting?

Brazel,

Nagasaka

2024

LCTT

View full text Add to dashboard Cite

Osimertinib is the current first-line treatment for EGFR-mutated NSCLC, however, patients frequently relapse due to acquired resistance mutations. Amivantamab is a bispecific antibody against EGFR and MET alterations. Lazertinib is a tyrosine kinase inhibitor active against EGFR mutations including common resistance mutations. The MARIPOSA trial was designed to study if the combination of amivantamab plus lazertinib in untreated epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) patients would provide improved progression-free survival. Here, we discuss the rationale for the study and the early results of MARIPOSA.

show abstract

What is early lung cancer?

Cited by 28 publications

References 77 publications

Advancements in the diagnosis and treatment of sub‑centimeter lung cancer in the era of precision medicine (Review)

Advancements in the diagnosis and treatment of sub‑centimeter lung cancer in the era of precision medicine (Review)

Real‐time in vivo cancer diagnosis using raman spectroscopy

MARIPOSA: Can Amivantamab and Lazertinib Replace Osimertinib in the Front-Line Setting?

Contact Info

Product

Resources

About